3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
5
Triple Negative Breast Neoplasms
4
Neoplasm Metastasis
4
Lymphoma
4
Carcinoma, Non-Small-Cell Lung
4
Neuroblastoma
3
Melanoma
3
Lung Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Gliosarcoma
2
Glioma
2
Glioblastoma
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Astrocytoma
2
Advanced Malignant Solid Tumor
2
Adenoma, Islet Cell
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rhabdoid Tumor
1
Resectable Pancreatic Cancer
1
Interventions
pembrolizumab
37
Gemcitabine
29
Nivolumab
20
Cisplatin
19
atezolizumab
15
avelumab
14
Docetaxel
13
enfortumab vedotin
10
Carboplatin
10
durvalumab
9
Magnetic Resonance Spectroscopy
9
Ipilimumab
8
Paclitaxel
7
Pemetrexed
6
toripalimab
5
cabozantinib
5
Fluorodeoxyglucose F18
5
sacituzumab govitecan
4
cabazitaxel
4
Taxes
4
vinflunine
3
tremelimumab
3
pemigatinib
3
X-Rays
3
Standard of Care
3
Specimen Handling
3
Radiotherapy
3
Mitomycin
3
Immunotherapy
3
Immunoglobulin G
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Transitional Cell
×
Colony-Stimulating Factors
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled